<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04704076</url>
  </required_header>
  <id_info>
    <org_study_id>19-29405</org_study_id>
    <nct_id>NCT04704076</nct_id>
  </id_info>
  <brief_title>Preventing Infant Malnutrition With Early Supplementation</brief_title>
  <acronym>PRIMES</acronym>
  <official_title>Preventing Infant Malnutrition With Early Supplementation, Aim 3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>International Partnership for Human Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Makerere University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bill and Melinda Gates Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Aberdeen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Worldwide, more than 50 million children under 5 years of age are wasted&#xD;
      (weight-for-length/height Z-score (WLZ) &lt;-2) and over 150 million children under 5 are&#xD;
      stunted (length/height-for-age Z-score (LAZ) &lt;-2); such wasting and stunting often begin&#xD;
      during infancy.1 Optimal nutrition can prevent wasting and stunting. Exclusive breastfeeding&#xD;
      (EBF) is widely recommended by community health workers, doctors and nurses and provides&#xD;
      optimal nutrition for most infants. However, early growth faltering is common for infants in&#xD;
      low and middle income countries (LMIC) and can both increase an infant's risk of early&#xD;
      mortality and also lead to deficits in attained height and weight throughout childhood. Thus&#xD;
      research is needed to determine the most efficacious strategy to promote healthy early growth&#xD;
      in LMIC.&#xD;
&#xD;
      Objective: The proposed study will test the efficacy of early small-volume supplementation&#xD;
      (ESVS) for increasing weight-for-age z-score (WAZ) at 1 month of age.&#xD;
&#xD;
      Methodology: The PRIMES pilot (Study 3) will be a randomized clinical trial enrolling infants&#xD;
      in Guinea-Bissau and Uganda weighing ≥2000g at birth. Infants weighing 2000-2499g at &lt;6 hours&#xD;
      of age (n=144; 72 per site) will be randomized on enrollment to one of two groups: 1) Early&#xD;
      Small-Volume Supplementation (ESVS intervention group), which consists of up to 59 mL formula&#xD;
      administered daily after breastfeeding through 30 days of age followed by EBF through 6&#xD;
      months of age; or 2) frequent exclusive breastfeeding without any food or fluid other than&#xD;
      vitamins, minerals and medications (control) through 6 months of age. Infants weighing&#xD;
      2500-3300g at &lt;6 hours of age will be weighed again at 4 days of age; those weighing &lt;2600g&#xD;
      at 4 days of age (n=180; 90 per site) will be randomized to the same intervention and control&#xD;
      groups. Weight will be measured on all enrolled babies at birth on Day 1 and at 4, 14, 30, 60&#xD;
      and 180 days of age and additional measures including height, MUAC, skinfolds, and hemoglobin&#xD;
      will be assessed at other time points. The study's primary outcome will be WAZ at 1 month of&#xD;
      age. Secondary outcomes will include WLZ at 1 month of age; WAZ, WLZ and LAZ through 6 months&#xD;
      of age; breastfeeding duration and infant intestinal microbiota.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 28, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Weight-for-age z-score (WAZ) at 30 days of age</measure>
    <time_frame>30 days of age</time_frame>
    <description>WAZ calculated according to WHO Child Growth Standards</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weight-for-length z-score (WLZ) at 30 days of age</measure>
    <time_frame>30 days of age</time_frame>
    <description>WLZ calculated according to WHO Child Growth Standards</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight-for-length z-score (WLZ) at 180 days of age</measure>
    <time_frame>180 days of age</time_frame>
    <description>WLZ calculated according to WHO Child Growth Standards</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight-for-age z-score (WLZ) at 180 days of age</measure>
    <time_frame>180 days of age</time_frame>
    <description>WAZ calculated according to WHO Child Growth Standards</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length-for-age z-score (LAZ) at 180 days of age</measure>
    <time_frame>180 days of age</time_frame>
    <description>LAZ calculated according to WHO Child Growth Standards</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whether or not breastfeeding continues at 180 days of age</measure>
    <time_frame>180 days of age</time_frame>
    <description>Continuation of breastfeeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abundance of B.infantis in intestinal microbiota</measure>
    <time_frame>30 days of age</time_frame>
    <description>Microbiota will be collected in DNA/RNA Shield Fecal Collection Tube containers (Zymo Research, Irvine, CA) and analyzed using 16S rRNA gene profiling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abundance of B.infantis in intestinal microbiota</measure>
    <time_frame>180 days of age</time_frame>
    <description>Microbiota will be collected in DNA/RNA Shield Fecal Collection Tube containers (Zymo Research, Irvine, CA) and analyzed using 16S rRNA gene profiling</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">324</enrollment>
  <condition>Underweight</condition>
  <condition>Wasting</condition>
  <condition>Stunting</condition>
  <condition>Breastfeeding</condition>
  <condition>Microbial Colonization</condition>
  <arm_group>
    <arm_group_label>Early, Small-Volume Supplementation (ESVS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Breastfeeding with up to 59 mL formula daily until 30 days of age, followed by recommendation to breastfeed exclusively through 6 months of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exclusive Breastfeeding</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Recommendation to breastfeed exclusively for 6 months without any other food or fluid except vitamins, minerals and medications</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ESVS</intervention_name>
    <description>Breastfeeding with up to 59-mL formula daily for the first 30 days, followed by exclusive breastfeeding through 6 months of age</description>
    <arm_group_label>Early, Small-Volume Supplementation (ESVS)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Exclusive breastfeeding</intervention_name>
    <description>Breastfeeding exclusively without any other food or fluid except vitamins, minerals and medications through 6 months of age</description>
    <arm_group_label>Exclusive Breastfeeding</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Infant &lt; 6 hours old&#xD;
&#xD;
          -  Infant birth weight 2000-2885g&#xD;
&#xD;
          -  Mother intends to breastfeed&#xD;
&#xD;
          -  Mother with negative HIV test&#xD;
&#xD;
          -  Mother lives in study catchment area and anticipates availability for all study visits&#xD;
&#xD;
          -  Mother ≥18 years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Twins and other multiples&#xD;
&#xD;
          -  Infant with known major congenital anomalies including orofacial clefts, neural tube&#xD;
             defects or congenital heart defects&#xD;
&#xD;
          -  Infant with WHO newborn and respiratory danger signs present:&#xD;
&#xD;
               -  Not feeding well&#xD;
&#xD;
               -  Convulsions&#xD;
&#xD;
               -  Very fast breathing ≥60 breaths/minute&#xD;
&#xD;
               -  Severe chest indrawing&#xD;
&#xD;
               -  No spontaneous movement&#xD;
&#xD;
               -  Lethargic or unconscious&#xD;
&#xD;
               -  Raised temperature &gt; 37.5 degrees Celsius&#xD;
&#xD;
               -  Hypothermia &lt;35.5 degrees Celsius&#xD;
&#xD;
               -  Any jaundice in first 24 hours of life or yellow palms or soles at any age&#xD;
&#xD;
               -  Head nodding, nasal flaring or grunting&#xD;
&#xD;
          -  Maternal psychiatric or psychosocial barrier to enrollment:&#xD;
&#xD;
               -  Contraindication to breastfeeding at each site as determined by a site's national&#xD;
                  or sub-national health authorities&#xD;
&#xD;
               -  Mothers unable or unwilling to complete all aspects of the protocol Infant&#xD;
                  enrolled in another study&#xD;
&#xD;
               -  Mother has had another infant enrolled in PRIMES&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>24 Hours</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valerie Flaherman, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Valerie Flaherman, MD, MPH</last_name>
    <phone>415-502-6266</phone>
    <email>valerie.flaherman@ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne Wanjuhi, MBBS, MS</last_name>
    <email>anne.wanjuhi@ucsf.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>International Partnership for Human Development</name>
      <address>
        <city>Bissau</city>
        <country>Guinea-Bissau</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Augusto Braima da Sa, MS</last_name>
      <email>saaugusto28@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Makerere University</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Victoria Nankabirwa</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Guinea-Bissau</country>
    <country>Uganda</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 7, 2021</study_first_submitted>
  <study_first_submitted_qc>January 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2021</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infections</mesh_term>
    <mesh_term>Malnutrition</mesh_term>
    <mesh_term>Infant Nutrition Disorders</mesh_term>
    <mesh_term>Thinness</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

